Abstract
Under the collaboration between National Tsing Hua University(NTHU) and Taipei Veterans General Hospital(TVGH), clinical trial of recurrent head-and-neck cancer by Boron Neutron Capture Therapy(BNCT) started in 2010. Until now 20 patients have been treated. This study is focused on the difference of calculation results between the in-house treatment planning system THORplan and SERA used in Japan and Finland. The source used in THORplan for clinical trial, y09, has space-dependent angular distribution. SERA, however, can not read in source with space-dependent at angular distribution. Therefore, THORplan and SERA were first compared by using Source 50c, a non space-dependent angular dependent neutron source. The results showed that compared with the SERA result, the dose rate calculated by THORplan at Tumor D80 location was higher by 4%, and the normal tissue maximum dose rate were lower by 3%. The estimated irradiation time was shorter by 4%, therefore the normal tissue maximum dose were lower by 5%～7%. When Source 50c was replaced by Source y09 in THORplan calculation, no significant difference was found. The difference of estimated irradiation time between THORplan and SERA remained within 4% and the normal tissue maximum dose were within 5%. Compared with THORplan, the major disadvantage of SERA is unable to simulate the treatment planning condition using patient collimator.